No Mo’ Nordisk: Ozempic Maker Rebrands as Novo, Promises New Culture

Novo Nordisk shot to corporate fame by trimming waistlines. On Monday, its name became the latest target for slimming down.

The Danish pharma giant, best known for blockbuster GLP-1 drug Ozempic, announced it is now simply Novo. Unfortunately, while rebranding can make words disappear, the same does not ring true for business challenges. A revamp of Novo’s corporate culture, promised as part of the rebrand, might help, though the details are thin so far.

What’s Old is Novo Again

The name change arrives with Novo shares down 15% in 2026, despite the propitious launch of the oral version of its obesity drug Wegovy, which is massively outselling rival Eli Lilly’s competing Foundayo. Novo needed this financial and symbolic victory after spending the past two years ceding market share to Indianapolis-based Lilly, which now dominates the overall weight-loss market, holding a 60.9% market share to Novo’s 38.8% in the second quarter, according to IQVIA data.

Meanwhile, the weight of Novo’s GLP-1 drugs in its portfolio is cause for concern. Earlier this month, Novo scrapped two trials for experimental cardiovascular drug ziltivekimab, once viewed by analysts as a $3 billion opportunity to diversify revenue beyond weight loss and diabetes. Morgan Stanley downgraded the stock to underweight after the trials were halted, citing the fact that three-quarters of Novo’s revenue comes from GLP-1 drugs facing patent cliffs in the early 2030s. To better navigate these hurdles, Novo’s new-ish name will come with an “updated” corporate culture:

• Novo said it will follow a new set of four principles it calls “The Novo Way.” They are customer obsession, competitiveness, clarity, and care and integrity; how the principles are applied to Novo’s operations is, for now, a crystal ball’s prerogative.
• The shorter, punchier name can be viewed as recognition that Novo’s position as a weight-loss leader has transformed it into a heavily consumer-facing company. So can the rebrand’s tagline, “Lasting Health Starts Now,” which evokes the immediacy of a consumer strategy in a market where US regulators have opened GLP-1 sales to direct-to-consumer and cash-pay telehealth programs.

Official and Unofficial: The pharma industry has had its share of concision-oriented rebrands in recent years. In 2022, GlaxoSmithKline became GSK, and Sanofi rebranded its rare diseases unit Sanofi Genzyme and vaccines unit Sanofi Pasteur under the parent name. While not official changes, Bristol Myers Squibb and Eli Lilly informally refer to themselves in branding and marketing materials as BMS and Lilly, respectively.